The limitations of DCE have been well set out by the authors, namely the cost and its limited specificity. Unlike in breast MRI, DCE curve-typing is limited because most tumors demonstrate a type II curve (2) and a number of benign prostate conditions such as prostatitis and benign prostatic hyperplasia can demonstrate a Type III curve. Essentially the updated recommendations relegate the role of DCE to that of assessment of indeterminate lesions in the peripheral zone, and even then there must be a corresponding abnormality on another sequence. However, before dismissing DCE-MRI completely we need to appreciate the advantages it may bring.